Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Stoke Therapeutics, Inc.NASDAQ: STOK
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows, but more slowly than its trailing trend
Q1 FY2026 capital expenditures of $353K (cash outflow) rose 132.2% year over year, behind the +153.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 52.2% from the prior quarter. Over 3 fiscal years it compounded at -44.7% a year.
Context
- Capital expenditures amounted to 0.4% of revenue in FY2025, down 0.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +132.2% toward the trailing-twelve-month pace of +153.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (670K) USD
- Year-over-year change
- -230.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (670K) | -230.0% |
| FY2024 | 2024-12-31 | (203K) | +87.4% |
| FY2023 | 2023-12-31 | (1.62M) | +59.2% |
| FY2022 | 2022-12-31 | (3.96M) | -230.2% |
| FY2021 | 2021-12-31 | (1.2M) | — |
Capital Expenditures vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +153.9% is the highest of 6, against a peer median of +24.6%.
- Capital expenditures amounts to 2.7% of revenue for STOK, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $71.85M USD | +29.1% | +36.8% | 7.5% | |
| LTM Jun 2026 | $13.39M USD | +24.6% | -32.7% | 8.6% | |
| LTM Mar 2026 | $981.99K USD | +43.1% | -19.2% | 1.4% | |
| LTM Mar 2026 | €955.79K EUR | +5.0% | +11.4% | 7.1% | |
| LTM Mar 2026 | $871K USD | +153.9% | -44.7% | 2.7% | |
| LTM Mar 2026 | $121K USD | -44.2% | -40.5% | — | |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| Peer median (excluding STOK) | — | +24.6% | -25.9% | 7.5% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| Deferred Income Tax | 172K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.45M | 22.85M | 25.26M | 27.47M | 32.24M |
| Change in Working Capital | 46K | 43.02M | (6.03M) | (28.14M) | 16.35M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (4.27M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.9M | 121K | (3.21M) | 3.09M | 21.29M |
| Other Working Capital | (2.85M) | 42.9M | (2.82M) | (31.23M) | (675K) |
| Other Non-Cash Items | 1.26M | 1.78M | 1.94M | 623K | 2.12M |
| Operating Cash Flow | (66.91M) | (31.87M) | (81.07M) | (86.85M) | 45.59M |
| Capital Expenditures | (1.2M) | (3.96M) | (1.62M) | (203K) | (670K) |
| Acquisitions (Net) | 75.23M | 45.34M | 0 | 0 | 0 |
| Purchases of Investments | (87.23M) | (201.32M) | 0 | (167.27M) | (322.72M) |
| Sales of Investments | 12M | 159.4M | 107.56M | 60M | 136.58M |
| Other Investing Activities | (75.23M) | (45.34M) | 0 | 0 | 0 |
| Investing Cash Flow | (76.43M) | (45.88M) | 105.95M | (107.48M) | (186.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.29M | 45.34M | 52.08M | 128.84M | 97.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | 1.07M | 926K | 2.25M | 0 |
| Financing Cash Flow | 1.28M | 46.41M | 53.01M | 131.09M | 97.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (142.05M) | (31.34M) | 77.89M | (63.23M) | (43.84M) |
| Free Cash Flow | (68.11M) | (35.83M) | (82.68M) | (87.05M) | 44.92M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.